Vidalista 5 mg

Description

Vidalista 5 mg contains the active ingredient Tadalafil 5mg, which is used to treat erectile dysfunction (ED) in men. It may also be used to treat the symptoms of Benign Prostatic Hyperplasia (BPH). Tadalafil increases the blood flow to the penis and helps achieve or sustain an erection. The effects of this drug are known to last for approximately 36 hours. This pill should be taken 30 minutes to 1 hour before any sexual activity.

How does Vidalista 5mg work?

Vidalista 5mg is used for the treatment of erectile dysfunction (ED) in men. It contains Tadalafil which helps relax the muscles around the pelvic area and increases the blood flow to the penis. It blocks the effects of the enzyme PDE5 and improves blood circulation throughout the body. Once the penis gets filled with blood, an erection is achieved. Sexual arousal is necessary for this drug to work properly.

Vidalista 5 mg Uses

Erectile dysfunction: It is a condition in which a man is unable to achieve or sustain an erection firm enough for sexual intercourse.
Benign prostatic hyperplasia: Also known as prostate gland enlargement, it causes urination difficulty.

Recommended dosage

Vidalista 5 mg tablets are taken orally with or without food. This pill is usually taken 30 minutes to 1 hour before any sexual activity.
If you are taking it to treat symptoms of BPH, your doctor might recommend you to take it daily.

Missed dose

If you are taking this drug for the treatment of ED, you are less likely to miss a dose. However, if you are taking it for the treatment of BPH, take the pill as soon as you remember. Unless it is time for your next dose, then skip it.

Overdose

If someone has overdosed and is facing severe side effects, seek medical help immediately.

Side effects

Vidalista 5mg tablets may cause certain side effects. Tell your doctor if these symptoms are severe or persist for long.
Mild side effects include:

• Dizziness
• Headaches
• Stuffy nose
• Nausea
• Flushing
• Diarrhoea

Serious side effects include

• Difficulty in breathing
• Vision problems
• Loss of hearing
• High blood pressure

Safety advice

Here are a few things to keep in mind before taking Vidalista 5. It is also advisable to consult your doctor before.

• People with kidney, liver, or heart problems should check with their doctor first.
• If you are allergic to any ingredients like Tadalafil, consult your doctor.
• Discuss your medical history with the doctor to avoid any side effects.
• Avoid drinking alcohol or grapefruit juice along with this medication.
• This medicine is not recommended for use in pregnant or breastfeeding women.

Drug interactions

Drug interactions can alter how a drug works or increase the risk of side effects. It is important to understand which medications your drug can interact with to minimize the risks. Talk to your doctor about your medical history. Here’s a list of drugs that interact with Vidalista 5mg.

• Certain drugs used to treat chest pain/angina (nitrates such as nitroglycerin, isosorbide)
• Recreational drugs called “poppers” containing amyl or butyl nitrite
• Alpha-blocker medication (such as doxazosin, tamsulosin)
• Azole antifungals (such as itraconazole, ketoconazole)
• HIV protease inhibitors (such as fosamprenavir, ritonavir)
• Macrolide antibiotics (such as clarithromycin, erythromycin)
• Hepatitis C virus protease inhibitors (such as boceprevir, telaprevir)
• Other medications or treatments for erectile dysfunction;
• Other medications or treatments for PAH
• Phenobarbital
• Phenytoin (Dilantin, Phenytek)
• Rifabutin (Mycobutin)
• Rifampin (Rifadin, Rimactane, in Rifamate, in Rifater)
• Sertraline (Zoloft)
• Telithromycin (Ketek)
• Verapamil (Calan, Covera,Verelan, in Tarka).

Storage instructions

• Keep the medication tightly sealed in its original container.
• Store in a cool, dry place.
• Keep it away from the reach of children and pets.

References

• Coward RM, Carson CC. Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag. 2008 Dec;4(6):1315-30. doi: 10.2147/tcrm.s3336. PMID: 19337438; PMCID: PMC2643112. https://www.dovepress.com/tadalafil-in-the-treatment-of-erectile-dysfunction-peer-reviewed-fulltext-article-TCRM
• Hatzimouratidis K. A review of the use of Tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction. Ther Adv Urol. 2014 Aug;6(4):135-47. doi: 10.1177/1756287214531639. PMID: 25083163; PMCID: PMC4054509.
  https://journals.sagepub.com/doi/10.1177/1756287214531639
• Gong B, Ma M, Xie W, Yang X, Huang Y, Sun T, Luo Y, Huang J. Direct comparison of Tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol. 2017 Oct;49(10):1731-1740. doi: 10.1007/s11255-017-1644-5. Epub 2017 Jul 24. PMID: 28741090; PMCID: PMC5603624.
  https://link.springer.com/article/10.1007/s11255-017-1644-5
• Frajese GV, Pozzi F, Frajese G. Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence. Clin Interv Aging. 2006;1(4):439-49. doi: 10.2147/ciia.2006.1.4.439. PMID: 18046921; PMCID: PMC2699638. https://www.atypon-link.com/DMP/doi/abs/10.2147/ciia.2006.1.4.439
• Wang Y, Bao Y, Liu J, Duan L, Cui Y. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. Low Urin Tract Symptoms. 2018 Jan;10(1):84-92. doi: 10.1111/luts.12144. Epub 2016 Nov 5. PMID: 29341503
  https://onlinelibrary.wiley.com/doi/10.1111/luts.12144
• Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009 Jun 9;119(22):2894-903. doi: 10.1161/CIRCULATIONAHA.108.839274. Epub 2009 May 26. Erratum in: Circulation. 2011 Sep 6;124(10):e279. Dosage error in article text. PMID: 19470885.
  https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.108.839274
• Sofikitis N, Kaltsas A, Dimitriadis F, Rassweiler J, Grivas N, Zachariou A, Kaponis A, Tsounapi P, Paterakis N, Karagiannis A, Skouros S, Giannakis I, Champilomatis I, Paschopoulos M, Daphnis D, Giakoumakis I, R Gabales M, M Chua JB, Lantin Iii PL, Mamoulakis C, Takenaka A. The Effect of PDE5 Inhibitors on the Male Reproductive Tract. Curr Pharm Des. 2021;27(23):2697-2713. doi: 10.2174/1381612826666200226121510. PMID: 32101115. https://www.eurekaselect.com/article/104866